Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Lombard Odier Investment Managers
https://www.lombardodier.com/home.html
Perhaps Conifer Management & Baillie Gifford dropped below 3% : O/S shares have increased from 283,614,110 to current 360,042,104 ?
--------------------
As at 24th October 2023
"Significant Shareholdings
Current significant shareholders are as follows:
Conifer Management, LLC 4.4%
Baillie Gifford & Co Limited 3.7%
As at 24th October 2023 the company has 283,614,110 ordinary shares of 10p each in issue."
Slowing replacing AS comments with CC comments .
https://avacta.com/investors/ceo-welcome/ 0 2024-05-01 14:10 +00:00
https://avacta.com/investors/key-information/ 0 2024-05-01 14:17 +00:00
https://avacta.com/investors/corporate-governance/ 0 2024-05-01 14:38 +00:00
https://avacta.com/investors/results-presentations/ 0 2024-05-01 14:45 +00:00
https://avacta.com/investors/investor-resources/ 0 2024-05-01 14:47 +00:00
Thanks good example -why not Avacta
https://www.pharmaceutical-technology.com/news/novartis-peptidream-peptide-deal/
£38M cash as at end March 24 : Would like to think deals will be done this year & certainly long before end 2025 ,so at the moment healthy cash reserves & diagnostics conributions will be cash positive .
Lots happening 2H2024 .
"[00:56:45.760]
-Christina Coughlin So this is correct. Back to my favourite slide. Based on the data that we've seen in the clinic, and that
includes both the PK, the efficacy, the safety, we have been working on the pipeline very hard internallyere. We describe there are multiple formats that we can everage the precision technology, not just the precision drug conjugates, but also Precision Plus, which is going to allow us to take, we mentioned immune mediated or targeted therapies as warheads, so not just a cytotoxic.
We also have the Precision ADC format, the Affirmer drug conjugate format. And so we are quite excited about how the pipeline is coming together. And we haven't disclosed the details yet.
But what I do commit to you is that in the second half of 2024, we will be disclosing the pipeline.We think it's pretty exciting with a couple of really novel programmes coming forward. And with that disclosure, we will also be describing time to the clinic and where we are with each of those programmes. So good question. And we very much look forward to that particular update in the second half of 2024"
Science will prevail - yes current market cap stinks - apparently " everything on the table " have you been dealt good or bad hand - your choice " stick ,fold or twist " I will stick with the company . It is all about for me the asset IP value & someone will pay to get their hands on Avacta proprietary technology .
Good luck everyone .
Get the phase one clinical data & then boom :
" We have hired our Chief Business Officer, Simon Bennett,and let me tell you, he is quite busy. The commercial deals that we've spoken about, these are really unlocked by these clinical data. And so there are multiple conversations ongoing. Progress is being made on multip le fronts in the pipeline"
Https://avacta.com/wp-content/uploads/2024/04/Avacta-Group-plc-Preliminary-Results-29Apr2024_final.pdf
" So at the end of March, we had circa 38 mil lion cash. That cash,based on our current runways, takes us through probably to the start of 2026"
"
Good Morning -very useful transcript from yesterday.
https://www.dropbox.com/scl/fi/36pr2bcwdrg7wqwchedq2/AVACTA-Prelims-and-Update-April-30th-2024.docx?rlkey=kbadjkv1w13h1ougizsobjeld&e=1&dl=0
Avacta team bit light on the ground to do any serious inhouse pipeline work . Maybe CC will cover that today ?
https://avacta.com/precision/therapeutics-team/
Seems obvious now that Avacta pre|CISIONTM platform will also be up for sale . Replaced CEO - No CMO, CDO, CSO seriously doubt they will take AVA6000 to phase 2 . Diagnostics also to be sold - So Avacta no more be gone within 12 months ( not sure about affimers maybe they could be be kept inhouse and licenced out to different companies .)
Hopefully pre|CISIONTM will command billion $ price-tag - Sorry to see Dr Smith depart - protectecting IP rights is in my opinion will be his great legacy - so thanks once again for the investment opportunity.
FYI
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,611 followers1,611 followers
5h • 5h •
In 2024, Launch Diagnostics celebrated its 34th anniversary as a major independent distributor within the specialist diagnostics industry. To be successful over three decades we must maintain the ability to adapt and grow as a business.
To facilitate this growth, we are proud to announce the official opening of our new modern facilities based in Crossways Business Park, Dartford. These new facilities reflect our investment and commitment to a modern, efficient, sustainable workplace environment, which includes quiet rooms, soft relaxation areas and offers our suppliers and customers the chance to experience our state-of-the-art Training and demo suite highlighting our innovative state -of-the -art precision diagnostic platforms.
A special highlight of the day was the opening of our official new premises by Helen Dent, CEO of The British In Vitro Diagnostic Association (BIVDA), who has been an integral part of our journey.
To all our suppliers, customers and employees, we thank you for being with us on our journey of expansion and excellence. Launch Diagnostics will continue to develop our level of expertise within the diagnostics industry whilst maintaining our commitment to deliver high quality tests, precision equipment and optimal patient care within the health services of the UK, ROI, France, Belgium and Germany."
Https://avacta.com/people/eliot-forster/ 1 2024-04-29 16:42 +00:00
https://avacta.com/people/christina-coughlin/ 1 2024-04-29 16:45 +00:00
Annual results will be as at "audited preliminary results for year ended 31st December 2023" Maybe also get some forward diagnostic guidance .
-------------------------
--Trinity Note :
https://rtfilesprod.blob.core.windows.net/originalnotes/Avacta%20Update%20231214.pdf?sv=2019-07-07&sr=b&sig=fqVH2eWKz0ubrJ0qDPvIzChxsyeEzo4k%2FdOJG7q9HoM%3D&se=2024-04-29T12%3A26%3A58Z&sp=r
"Incorporation of the Coris acquisition (June 2023 Lighthouse) has led to an uptick in our Diagnostics DCF (over and above rolling forwards in time) largely owing to the higher revenues from the combined businesses, plus from future operational synergies. Recall Coris’ FY22 revenues were £4.6m (unaudited), with a c 50% gross margin, an EBITDA of £0.35m, and a £0.02m net loss. Hence, together with Launch Diagnostics (fully consolidated FY23e revenues of £17m), we expect combined fully consolidated FY24e Diagnostics revenues of c £23-24m; more details on our Coris forecasts follow in the next section of this note. "
"Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:
“These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION™ platform to avoid normal tissue effects while concentrating the toxin in the tumour microenvironment.”
"Lee Cranmer MD, PhD, FACP, Curtis and Elizabeth Anderson Endowed Professor in Sarcoma Research, University of Washington and Professor and Director of Sarcoma Oncology, Fred Hutchinson Cancer Center, commented:
“I am encouraged by the initial data with AVA6000 in the Phase 1 trial and look forward to working with my fellow investigators and our collaborators at Avacta to understand better the optimal dosing for this novel approach to targeted cancer therapy.”
Good Morning . Great little company & product - Proactive CEO - increasing recurring revenues the number of LeakBots installed means company heading in the right direction . Nice investment to hold .
Good luck ONDO & shareholders .
https://twitter.com/foster_ideas/status/1784837822991479212
"𝗘𝗦𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 has started!
Interested in learning more about rapid tests? Or exploring potential partnerships?
Come and meet Sébastien (COO) and Audrey (Marketing manager) at booth F-10 ! Looking forward to meeting you!
#ESCMID2024 #AntiMicrobialResistance #MedicalBiotechnology #RapidDiagnostics #HealthcareInnovation"
https://www.linkedin.com/feed/update/urn:li:activity:7189928704683204608/
Would be nice to see some good results from Diagnostics .
"David Wilson
@DSWilsonDx
Delighted to be supporting
@avacta
Group companies
@corisbio
, Launch Diagnostics UK, Launch Diagnostics France SAS, and Launch Diagnostics Deutschland GmbH at ESCMID Global 2024. #eccmid2024 #ESCMIDGlobal2024"
https://twitter.com/DSWilsonDx